SENORES1,468.00

Senores Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSANOFIINNOVACAPMOREPENLABIOLCPFDCPGHLSANOFICONRORCHPHARMAMcap ₹6,760 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations398.3632.6691.7
Other Income19.347.129.7
Total Income417.5679.7721.4
Expenses
+ Cost of Materials Consumed91.6114.3141.3
+ Purchases of Stock-in-Trade89.8137.3118.6
+ Changes in Inventories-0.80.1-3.8
+ Employee Benefit Expense60.4112.3120.5
+ Finance Costs21.625.027.2
+ Depreciation & Amortisation16.831.335.2
+ Other Expenses67.5100.4110.4
Total Expenses346.9520.6549.3
EBITDA89.7168.3204.8
EBIT72.9137.1169.6
Profit
PBT before Exceptional Items70.6159.1172.1
Pretax Income70.6159.1172.1
+ Current Tax15.619.924.9
+ Deferred Tax-3.317.616.4
Tax Expense12.237.641.3
Net Income58.3121.5130.8
+ Net Income — Continuing Ops58.3121.5130.8
+ Other Comprehensive Income-3.529.229.2
Total Comprehensive Income54.8150.7160.1
Net Income to Common0.094.8
Minority Interest0.0-0.6
Per Share
Basic EPS16.1226.3928.40
Diluted EPS16.1226.3928.39
Other Comprehensive Income — detail
+ Other Comprehensive Income-3.529.229.2
+ Items NOT to be Reclassified to P&L-0.0
+ Tax on Items NOT to be Reclassified0.00.0
+ Items to be Reclassified to P&L29.2
+ Tax on Items to be Reclassified3.50.08.3
Comprehensive Income — Owners of Parent0.054.2
Comprehensive Income — Non-controlling Interests0.0-3.2
Per Share — as-filed variants
Basic EPS — Continuing Operations16.1226.3928.40
Diluted EPS — Continuing Operations16.1226.3928.39
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit217.6381.0435.7
Gross Margin %54.6360.2262.99
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)70.6159.1172.1
Net Income Adj (tax-effected)58.3121.5130.8
EPS Adj16.1226.3928.40
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.00
Paid Up Equity Capital46.146.146.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.